ENABLE's initial
objectives:
To identify three leads and
two development candidates, and progress one
compound into preclinical and phase I clinical studies - were
surpassed with
- 6 lead
declarations
- 3 candidate
declarations
- 2
compounds into preclinical GLP studies
- 1 phase I
study completed
Dissemination
activities
The entire ENABLE team is busy discussing,
presenting and writing. Find a selection of the results
below:
Publications
-
Page, M.G.P.; Bush, K. (2014): Discovery and
development of new antibacterial agents targeting Gram-negative
bacteria in the era of pan-drug resistance: is the future
promising?, Curr. Op. Pharm. 2014; 18; 91-97
- Kostyanev, T. et al
(2016):
The Innovative Medicine Initiative (IMI) New Drugs for Bad Bugs
(ND4BB) programme - European Public Private Partnership for the
Development of New Strategies to Tackle Antibiotic Resistance,
J Antimicrob Chemother (2016) 71 (2): 290-295.
- Bill, R.M., vab der Haar, T.
(2015):
Hijacked
then lost in translation: the plight of the recombinant host cell
in membrane protein structural biology projects, Current
Opinion in Structural Biology Volume 47
- Kitchen, P. et al (2015):
Beyond
water homeostasis: Diverse functional roles of mammalian
aquaporins, Biochimica et Biophysica Acta (BBA) -
General Subjects
- Rabanal, F. et al
(2015):
A bioinspired peptide
scaffold with high antibiotic activity and low in vivo
toxicity,
Nature Scientific Reports | 5:10558 | DOI:
10.1038/srep10558
-
Uppsala University (2015): A
world without antibiotics, Pre-conference
publication: Uppsala health Summit
-
Kitchen, P. et al (2016): Structural
Determinants of Oligomerization of the Aquaporin‐4 Channel.
Journal of Biological Chemistry
-
Grau‐Campistany, A.et al (2016):
Tryptophan‐containing lipopeptide antibiotics derived from
polymyxin B with activity against Gram positive and Gram negative
bacteria. Biochimica et Biophysica Acta
(BBA)‐Biomembranes 1858 (2), 333–343 (2016)
-
Rabanal, F. et al (2016): Therapeutic
Potential of antimicrobial peptides in "New Weapons to Control
Bacterial Growth, Springer International Publishing
Switzerland, 2016
-
Rudilla, H. et al (2016): Synergistic
antipseudomonal effects of synthetic peptide AMP38 and carbapenems
Molecules
-
Kostyanev et al (2016): The Innovative
Medicines Initiative’s New Drugs for Bad Bugs programme:
European public–private partnerships for the development of new
strategies to tackle antibiotic resistance, J Antimicrob
Chemother 2016; 71: 290–295
- Chan
et al (2017): Thiophene
antibacterials that allosterically stabilize DNA-cleavage complexes
with DNA gyrase. In: Proc. Natl. Acad. Sci. USA May
30;114(22).
-
Rabanal et al (2017): Design, Synthesis and Activity of New
Polymyxins, in: Proceedings 2017, 1(6), 662;
doi:10.3390/proceedings106066
-
Segovia et al (2017): Design of New Polymyxins with Reduced
Nephrotoxicity, in: Proceedings of the 3rd Int. Electron. Conf.
Med. Chem., 1–30 November 2017;
Sciforum Electronic Conference Series, Vol. 3, 2017 ;
doi:10.3390/ecmc-3-04689
- Vaara
et al (2017): The polymyxin derivatives NAB739 and NAB815 are more
effective than polymyxin B in 3 murine Escherichia coli
pyelonephritis, in: J Antimicrob Chemother. 2018 Feb
1;73(2):452-455. doi: 10.1093/jac/dkx394.
- Vaara,
M., Vaara, T. and Tyrrell, J.M. (2017):
Structure-activity studies on polymyxin derivaties carrying three
positive charges only reveal a new class of compounds with strong
antibacterial activity. In: Elsevier, Peptides, Volume 91, May
2017, Pages 8-12
-
Jeannot, F. et al (2018): Imidazopyrazinones
(IPYs): novel non-quinolone bacterial topoisomerase inhibitors
showing partial cross-resistance with quinolones. In: J Med
Chem. 2018 Apr 26;61(8):3565-3581. doi:
10.1021/acs.jmedchem.7b01892.
- Dumont
et al (2018):
Mechanistic aspects of maltotriose-conjugate translocation to the
Gram-negative bacteria cytoplasm. In: Life Science
Alliance, DOI: 10.26508/lsa.201800242
- Racine
et al (2018): In vitro and In vivo
characterization of NOSO-502, a novel inhibitor of bacterial
translation. In: Antimicrob Agents Chemother.
2018 Aug 27;62(9), doi: 10.1128/AAC.01016-18
Articles & Press
Releases
- Rex, J.H. (2014):
ND4BB: addressing the antimicrobial resistance
crisis, Nature Reviews Microbiology 12,
231-232
- Press releases (2014): €85 million European
programme targets novel antibiotic, Aston, Biomol, CSIC, EBN,
Liege, Medina, Northern Antibiotics, OTC, Asclepia, SP,
Redx
- Karlén, A. (2014): Swedish researchers makes an
attempt to tackle a problem of the world, Article in Economic
magazine
- Karlén, A., Hughes, D. (2014): Non-even fight
against resistance, Article in popular science magazine
“Naturvetaren”
- Karlén, A. (2014):
Svenska forskare tar itu med världsproblem. Di
Almedalen.
- ENABLE participants (2014): Large effort in
antibiotic research, Swedish Radio – Science (20 minutes special on
ENABLE and hurdles of developing an antibacterial drug)
- Yli-Kauhaluoma, J (2014): Uudet antibiootit
haussa eurooppalaisena yhteistyönä, University of
Helsinki
- Yli-Kauhaluoma, J (2014): Suomen Lääkärilehti -
Finnish Medical Journal: Uusia antibiootteja etsitään
eurooppalaisessa yhteistyössä, University of Helsinki
- Kiuru, P. (2014): Antibiootin kehitys on
kilpajuoksua, Satakunnan Kansa (the 2nd oldest Finnish daily
newspaper)
- Kiuru, P. (2014): Kuuden vuoden kilpajuoksu
muuntuvia bakteereita vastaan, Aamulehti (Front page news
story)
- Horizon Magazine (2014): Complex molecules
could beat drug resistant bacteria.
- Press release UB (2015):
UB
researchers develop a new family of bioinspired antibiotic
compounds.
- European Biotechnology News
(2015): Time is running out.
- Press release Nosopharm (2015):
Nosopharm joins European Gram-negative
Antibacterial Engine (ENABLE) project to combat antibiotic
resistance, Nosopharm
- Uppsala University (2015): The Drug Push.
Interview in Science, 2015, Vol 348,
850-853
- ENABLE Press Release (2017): Three lead structures from
SMEs identified for novel antibiotics
- Nordic Life Science Magazine
(2017):
Antibiotic advances from new drugs 4 bad bugs
- ENABLE Juvabis Press Release (2018): Tackling Antimicrobial
Resistance: ENABLE Selects First Clinical Candidate
- ENABLE Mutabilis Press
Release (2019): ENABLE
selects new antibiotic candidate
- ENABLE Juvabis Press
Release (2019): Swiss
start-up Juvabis announces start of Phase I study of its
best-in-class aminoglycoside antibiotic apramycin
- ENABLE Press Release
(2020):
Goals achieved - Mission continues
- ENABLE Juvabis
(2020):
Juvabis announces positive Phase 1 results of EBL-1003 in the
Innovative Medicines Initiative's ENABLE Consortium
- ENABLE Mutabilis
(2021):
Mutabilis' EBL-1463 programme graduates from ENABLE with
Development Candidate and continues to progress with funding and
support from CARB-X
Lectures &
Presentations
- Karlén, A. (2014): ENABLE (IMI) presentation of
activities, seminar in Brussels
- Karlén, A. (2014): ENABLE - A European
antibacterial drug discovery platform, Lecture at Uppsala
University
- Karlén, A. (2014): Tackling Antimicrobial
Resistance, Lecture in Stockholm
- Karlén, A. (2014): New antibiotics- a common
responsibility or the responsibility of the industry, Lecture at
antibiotic seminar in Gotland,
- Karlén, A. (2014): IMI project experience:
"Project ENABLE: European Gram-negative Antibacterial Engine,
Lecture at IMI seminar in Oslo
- Karlén, A. (2014): Examples of partnerships
between public and private partners - Innovative Medicine
Initiative, Lecture at antibiotic seminar in Stockholm
- Karlén, A. (2015):Are collaborations in
Public-Private Partnerships a model for discovery of new
antibiotics, Lecture at seminar in Stockholm - The Royal Swedish
Academy of Engineering Sciences (IVA)
- Schipper, N. (2014): Framtidens infektionshot
kräver gränslösa samarbeten, Presentation at Swedish National Life
Science days
-
Genilloud, O. (2014): Discovery of Novel
Antibacterials from microbial natural Products, Presentation at
ICAAC2014
-
Stokes, N. (2014): Innovative approaches
from industry: Developing new treatment, Presentation at BSAC AMR
Round Table series
- Hughes, D. (2014): Antibiotics and resistance,
University of Uppsala
- Maxwell, T. (2014): Combating AMR: how can
topoisomerases and insect gut bacteria help?,
Presentation
- Stavenger, R.
(2015): Current
European Collaborative Plans: ENABLE Keystone Symposia on
Gram-Negative Resistance Granlibakken, Tahoe City (USA)
- Asclepia (2015): Collaboration and funding to
clinical trials for European anti-infective Gram negative
programmes, Lecture: Innova Balt Drug Discovery conference
Riga
- Asclepia (2015): Collaboration and Funding
through Preclinical Development and Phase I Clinical Trial for
Anti-Infective Gram-Negative Programs, Lecture: Re-
Entering Antibacterial Drug Development Summit,
Boston, MA
-
EBN (2015): Webinars on Funding for Gram negative
anti-infective programmes
- Yli-Kauhaluoma, J. (2015): Professori Jari
Yli-Kauhaluoma pitää juhlapuheen Karvian kotiseutujuhlassa,
Helsinki
- Medina (2015): The challenge
of discovering and developing novel microbial natural product
antibiotics to fight infectious diseases, Lecture: 5th CPA -
RSC
Symposium on Antibacterial Agents: Chemistry and
Mechanism of Action.
- Uppsala (2015): IMI-ENABLE: A
European Antibacterial Drug Discovery Platform, Lecture at
ICAAC2015 San Diego
- Uppsala (2015): Antibacterial drug discovery and
development. Challenges, opportunities and ways forward., Lecture
at AIMECS 2015: 10th AFMC International Medicinal Chemistry
Symposium, Jeju, Korea
- Uppsala (2015):
Experiences from
Horizon 2020 and IMI funded projects, Lecture at "National
Information Day on Health, demographic change and well-being in
Horizon 2020"
- Uppsala (2015): ENABLE - European Gram Negative
AntiBacterial Engine, Participate in 10th European Workshop in Drug
Design in Sienna (XEWDD). Present
Poster on ENABLE. Discuss ENABLE computaitional
chemistry platform and training in use of program developed by
ENABLE partner.
-
CNB (2016): Bacterial celldivision: Orchestrating
the ring cycle, EMBO Workshop Prague
- EBN (2016): Workshop: Showcasing global
anti‐infective innovation at the BIO Convention
- GSK (2016): IMI TRANSLOCATION & ENABLE:
Collaborative Drug Discovery in Action, Oral presentation at
workshop to take aim at Bacteria, Lehigh University,
USA
- JIC (2016): DNA Topoisomerases in Bacteria and
Plants: Mechanism and Drug Targeting, Lecture: Univ W.
Australia, Perth
- JIC (2016): Exploiting DNA topoisomerases for
antibiotic development, Lecture University of Sydney
- JIC (2016): New ways to target DNA gyrase: a
well‐validated target for antimicrobial chemotherapy, Lecture:
Gordon Research Conference, Sunday River, Maine, USA
- JIC (2016): Supercoils and superbugs: exploiting
DNA topoisomerases as targets for antibacterial
chemotherapy, Lecture: Trinity College, Dublin,
Ireland
- University of Uppsala (2016): The Swedish
contribution to IMI‐ENABLE: A European antibacterial drug discovery
platform, Lecture:Embassy of Sweden, Washington DC,
USA
- University of Uppsala, GSK (2016): Frontiers in
Antibiotic Drug Discovery (FiADD, Symposium: Antibacterial
Drug Discovery, Stockholm Sweden
- University of Uppsala (2016): Challenges and
progress inthe development of novel Gram‐negative antibiotics.
Lecture at The Norwegian
Academy of Science and Letters (DNVA) in
Oslo, Norway, “Turning the tide of Antimicrobial Resistance
Conference – TTA goes Nordic”
- Bacqué, E.: IMI-ENABLE: A
European Antibacterial Drug Discovery Platform.
- Stavenger, R.:
Addressing the challenges of antibacterial R&D through
public-private partnerships at the BIO convention.
- Schofield, C. (2017): From Antibiotics to Oxygen
Sensing and Back Again, seminar at the University of
Durham
- Karlén, A. (2017): The ENABLE project.
Presentation at the Berlin Conference on Novel
Antimicrobials.
- Griestop, L. (2017): The ENABLE project.
Presentation at the General Assembly of the EU funded PharmaSea
project.
- Bacqué, E. (2017): The ENABLE project.
Presentation at the Joint Programming Initiative on Antimicrobial
Resistance (JPIAMR) during the “Early Discovery of New Antibiotics
Workshop”
- Uppsala University (2017)- Interview for a report
about ENABLE in the Nordic Life Sciences titled "Antibiotic
Advances"
- Brem, J. (2017): "Tackling anti-microbial
resistance, development of novel metallo-ß-lactamase inhibitors",
presentation at PSWC 2017
- Tyrrell, J. (2018): Presentation of ENABLE at
Oxford university on July 18th.
- Karlén, A (2018): Presentation of ENABLE at the
Almedalen Week in Visby, Sweden from July 1st - July
7th.
- Karlén, A. & Bölcker, K. (2018): ENABLE
Präsentation auf der Berlin Conference on AMR in
Berlin
- Bacqué, E. (2018): Presentation of ENABLE at the
Innovative Medicines Initiative2 (IMI2) AMR
Accelerator‐Expert‐Workshop in Bonn on June 29th.
- Schofield, C. (2018): Presentation of ENABLE at
the Innovative Medicines Initiative (IMI) event in Brussels on June
27th: celebrating 10 years of medical
innovations.
- Maxwell, T. (2018): Presentation at the Gordon
Research Conference on DNA Topoisomerases in Biology &
Medicine: "Microcin B17, a Microbial Toxin that Targets DNA Gyrase:
Activity, Biosynthesis and Impact on Human Health"
- Baranczewski, P. (2018): Presentation of the
DMDG-SPS Joint meeting in Göteborg, 16-18 October 2018
- Nilsson, C. (2018): Presentation at the Swedish
Veterinary Institute on their Research Days
- Schofield, C. (2018): “From Penicillins to
Epigenetics – Adventures at the Interface ofChemistry and Biology”,
presentation at the University of Queensland, Brisbane,
Australia
- Schofield, C. (2018): “Structural, Functional and
Inhibition Studies on Enzymes Involved in the Regulation of Protein
Biosynthesis”, presentation at the University of Queensland,
Brisbane, Australia
- Schofield, C. (2018): “From Penicillins to
Epigenetics – Adventures at the Interface of Chemistry and
Biology”, presentation at Adelaide University, Adelaide,
Australia
- Schofield, C. (2018): “From Penicillins to
Epigenetics – Adventures at the Interface of Chemistry and
Biology”, presentation at Sydney University, Sydney,
Australia
- Schofield, C. (2018): “From Penicillins to
Epigenetics – Adventures at the Interface of Chemistry and
Biology”, presentation at Institut Pasteur, Paris,
France
- Schofield, C. (2018): “From Penicillins to
Epigenetics – Adventures at the Interface of Patents Conferences
Chemistry and Biology”, presentation University of Dundee,
Dundee
Patents
WO2018/215800 -
(Link)
"The present invention relates to certain
compounds that function as inhibitors of
bacterial metallo-beta-lactamases. The present invention also
relates to processes for
the preparation of these compounds, to
pharmaceutical compositions comprising them,
and to their use in the treatment of a bacterial
infection."
"The present invention relates to compounds of
Formula (I) that function as inhibitors of
bacterial metallo-beta-lactamases. The present invention also
relates to processes for
the preparation of these compounds, to pharmaceutical compositions
comprising them,
and to their use in the treatment of a bacterial infection.
(Formula (I))"
Posters
Posters
- UIT (2015): Combating antibiotic
resistance
- GSK (2016): IMI ENABLE: The European
Gram-Negative AntiBacterial Engine, Poster Presentation at Melinda
and Bill Gates Foundation Grand Challenges.
- Kiuru, P. (2016): ENABLE: Northern Antibiotics
Polymyxin Programme, Flash poster presentation at the symposium on
frontiers on antibiotic drug discovery (FiADD) in
Stockholm
- University of Uppsala (2016): Gordon
Research Conference: New Antibacterial Discovery & Development,
Poster presentation, Gordon Research Conference, Renaissance
Tuscany Il Ciocco in Lucca (Barga) Italy
- Stavenger, R. (2016): IMI ENABLE: The
European Gram-Negative AntiBacterial Engine presented at BMGF Grand
Challenges Annual Meeting, Oct 2016,
London
- Bölcker, K. (2017): Poster
presentation ENABLE at the ECCMID in
Vienna
- Gising, J. and Karlén, A. (2018): ENABLE –
European Gram Negative AntiBacterial
Engine
- Racine et al (2018): NOSO-502, a novel
antibacterial compound active against
Carbapenem-Resistant-Enterobacteriaceae.
- Salisbury et al (2018): In Vitro Evaluation
of Novel Bacterial Topoisomerase
Inhibitors
Video